The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML)

[1]  A. Tefferi,et al.  Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation , 2019, Haematologica.

[2]  A. Tefferi,et al.  Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation , 2019, Haematologica.

[3]  S. Khozin,et al.  Real-world Data for Clinical Evidence Generation in Oncology. , 2017, Journal of the National Cancer Institute.

[4]  M. Cazzola,et al.  Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. , 2016, Blood.

[5]  M. Cazzola,et al.  Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. , 2016, Blood.

[6]  P. Valent,et al.  Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors , 2016, Leukemia.

[7]  P. Valent,et al.  Chronic myelomonocytic leukemia patients with RAS pathway mutations show high in vitro myeloid colony formation in the absence of exogenous growth factors , 2016, Leukemia.

[8]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[9]  E. Solary,et al.  An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies , 2015, Blood Cancer Journal.

[10]  D. Steensma,et al.  Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies , 2015, Current opinion in hematology.

[11]  A. Tefferi,et al.  Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review , 2014, British journal of haematology.

[12]  A. Tefferi,et al.  Chronic myelomonocytic leukaemia: a concise clinical and pathophysiological review , 2014, British journal of haematology.

[13]  R. Laborde,et al.  Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes , 2013, Leukemia.

[14]  R. Laborde,et al.  Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes , 2013, Leukemia.

[15]  D. Birnbaum,et al.  Prognostic score including gene mutations in chronic myelomonocytic leukemia. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  O. Abdel-Wahab,et al.  GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia. , 2013, Blood.

[17]  L. Arenillas,et al.  Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. , 2013, Blood.

[18]  F. Atem,et al.  Activity of azacitidine in chronic myelomonocytic leukemia , 2011, Cancer.

[19]  M. Fleming,et al.  Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. , 2010, Blood.

[20]  M. Fleming,et al.  Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia. , 2010, Blood.

[21]  S. Corti,et al.  RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant , 2010, Clinical Cancer Research.

[22]  S. Corti,et al.  RAS Mutations Contribute to Evolution of Chronic Myelomonocytic Leukemia to the Proliferative Variant , 2010, Clinical Cancer Research.

[23]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[24]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[25]  Valeria Santini,et al.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. , 2009, The Lancet. Oncology.

[26]  K. Geissler,et al.  Diagnostic and prognostic value of colony formation of hematopoietic progenitor cells in myeloid malignancies , 2003, Wiener Klinische Wochenschrift.

[27]  J. Bennett,et al.  Chronic myelomonocytic leukemia in the light of the WHO proposals. , 2007, Haematologica.

[28]  G. Nolan,et al.  K-RasG12D expression induces hyperproliferation and aberrant signaling in primary hematopoietic stem/progenitor cells. , 2007, Blood.

[29]  H. Kantarjian,et al.  Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia , 2007, Cancer.

[30]  H. Kantarjian,et al.  Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia , 2007, Cancer.

[31]  Menggang Yu,et al.  Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. , 2005, Blood.

[32]  M. L. Le Beau,et al.  Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. , 2004, Blood.

[33]  M. L. Le Beau,et al.  Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. , 2004, Blood.

[34]  K. Lechner,et al.  High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival , 2003, Annals of Hematology.

[35]  K. Lechner,et al.  High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival , 2003, Annals of Hematology.

[36]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[37]  D. Hossfeld.  E.S. Jaffe, N.L. Harris, H. Stein, J.W. Vardiman (eds). World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues , 2002 .

[38]  Terry L. Smith,et al.  Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. , 2002, Blood.

[39]  Terry L. Smith,et al.  Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. , 2002, Blood.

[40]  B. Pégourié,et al.  A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group. , 1996, Blood.

[41]  B. Pégourié,et al.  A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group. , 1996, Blood.

[42]  M. Rogy,et al.  Interleukin 10 inhibits growth and granulocyte/macrophage colony- stimulating factor production in chronic myelomonocytic leukemia cells , 1996, The Journal of experimental medicine.

[43]  M. Rogy,et al.  Interleukin 10 inhibits growth and granulocyte/macrophage colony- stimulating factor production in chronic myelomonocytic leukemia cells , 1996, The Journal of experimental medicine.

[44]  O. Haas,et al.  Colony growth characteristics in chronic myelomonocytic leukemia. , 1988, Leukemia research.

[45]  O. Haas,et al.  Colony growth characteristics in chronic myelomonocytic leukemia. , 1988, Leukemia research.

[46]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.

[47]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.